Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Combined With Lenvatinib and Sintilimab for HCC With PVTT
NCT04618367Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of lenvatinib and sintilimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Progression free survival rate at 6 months. Started Jan 2021; status: completed.
02
Drugs
lenvatinibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04618367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04618367.